Skip to main content

Biogen stock price and financials

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026
Market value
$37.52B
P/E
107.98
EV / EBITDA
26.68
Beta · 1 year
0.37
Return · 1 year
+56.9%
52-week range$160.36 — $261.00

Share price close 16 Nov 2026

+8.0%1 monthHigh $254.87Low $232.65
$230$240$250$260Q3 FY2026 report filed 28 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+31.8%6 monthsHigh $254.87Low $187.80
$180$200$220$240$260Q2 FY2026 report filed 29 Jul 2026Q3 FY2026 report filed 28 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+44.5%year to dateHigh $254.87Low $164.42
$150$175$200$225$250$275Q4 FY2025 report filed 6 Feb 2026Q1 FY2026 report filed 29 Apr 2026Q2 FY2026 report filed 29 Jul 2026Q3 FY2026 report filed 28 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+51.7%1 yearHigh $254.87Low $164.42
$150$175$200$225$250$275Q4 FY2025 report filed 6 Feb 2026Q1 FY2026 report filed 29 Apr 2026Q2 FY2026 report filed 29 Jul 2026Q3 FY2026 report filed 28 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+10.7%3 yearsHigh $267.71Low $113.38
$100$150$200$250$300Q4 FY2023 report filed 14 Feb 2024Q1 FY2024 report filed 24 Apr 2024Q2 FY2024 report filed 1 Aug 2024Q3 FY2024 report filed 30 Oct 2024Q4 FY2024 report filed 12 Feb 2025Q1 FY2025 report filed 1 May 2025Q2 FY2025 report filed 31 Jul 2025Q3 FY2025 report filed 30 Oct 2025Q4 FY2025 report filed 6 Feb 2026Q1 FY2026 report filed 29 Apr 2026Q2 FY2026 report filed 29 Jul 2026Q3 FY2026 report filed 28 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
−19.8%10 yearsHigh $396.64Low $113.38
$100$200$300$400Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Biogen reported revenue of $9.89 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.2% from fiscal 2024. Net income was $1.29 billion and diluted earnings per share $8.79.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $2.80 billion, up 10.6% from a year earlier.

Figures from Biogen's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 28 Oct 2026.

Against Health Care

Growth
Bottom quarter
Revenue −6.0% a year over five years · 37th of 37
Profitability
Upper half
Return on invested capital 11.5%, five-year average · 18th of 38
Balance sheet
Bottom quarter
Net debt 3.7× EBITDA · 33rd of 38
Valuation
Dearer than most
P/E 108.0 · 35th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$9.89B+2.2%
Net income
$1.29B−20.8%
Diluted EPS
$8.79−21.4%
Gross margin
75.7%−0.4 pts
Free cash flow
$2.05B−24.7%
Net debt
$2.84B+9.6%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$5B$10B$15BRevenue, FY16: $11.45BNet income, FY16: $3.7BFY16Revenue, FY17: $12.27BNet income, FY17: $2.54BFY17Revenue, FY18: $13.45BNet income, FY18: $4.43BFY18Revenue, FY19: $14.38BNet income, FY19: $5.89BFY19Revenue, FY20: $13.44BNet income, FY20: $4BFY20Revenue, FY21: $10.98BNet income, FY21: $1.56BFY21Revenue, FY22: $10.17BNet income, FY22: $3.05BFY22Revenue, FY23: $9.84BNet income, FY23: $1.16BFY23Revenue, FY24: $9.68BNet income, FY24: $1.63BFY24Revenue, FY25: $9.89BNet income, FY25: $1.29BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 28 Oct 2026 · Full results →

Revenue
$2.80B+10.6% on a year
Gross margin
73.3%−0.1 pts on a year
Operating income
−$9.00M−102% on a year
Net income
−$20.60M−104% on a year
Diluted EPS
−$0.14−104% on a year
Free cash flow
$600.4M−51.0% on a year

Comparable companies All of Health Care →

Biogen beside the other S&P 500 members in Biotechnology, by market value.

Biogen and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
BiogenBIIB$37.52B+1.2%+56.9%+2.3%3.4%108.0
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1
AmgenAMGN$253.8B−0.3%+38.5%+8.2%24.1%27.0
Gilead SciencesGILD$210.2B+0.1%+36.2%+6.5%−12.5%—
IncyteINCY$24.67B−0.6%+11.7%+24.9%6.7%61.2
ModernaMRNA—−3.4%+736%———
Regeneron PharmaceuticalsREGN—+0.4%+40.2%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%50%100%75.7%18.8%13.1%FY16FY19FY22FY25

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Biogen income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$11.45B$12.27B$13.45B$14.38B$13.44B$10.98B$10.17B$9.84B$9.68B$9.89B
Revenue growth+6.4%+7.2%+9.6%+6.9%−6.5%−18.3%−7.4%−3.3%−1.6%+2.2%
Gross profit$9.97B$10.64B$11.64B$12.42B$11.64B$8.87B$7.90B$7.30B$7.37B$7.49B
Operating income$5.15B$5.35B$5.89B$7.04B$4.55B$2.84B$3.84B$1.61B$2.25B$1.86B
Net income$3.70B$2.54B$4.43B$5.89B$4.00B$1.56B$3.05B$1.16B$1.63B$1.29B
Diluted EPS$16.93$11.92$21.58$31.42$24.80$10.40$20.87$7.97$11.18$8.79
Gross margin87.1%86.7%86.5%86.4%86.6%80.8%77.6%74.2%76.1%75.7%
Operating margin45.0%43.6%43.8%49.0%33.8%25.9%37.7%16.4%23.2%18.8%
Net margin32.3%20.7%32.9%41.0%29.8%14.2%29.9%11.8%16.9%13.1%

Cash flow

Biogen cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$4.59B$4.55B$6.19B$7.08B$4.23B$3.64B$1.38B$1.55B$2.88B$2.20B
Capital expenditure$616.1M$867.4M$770.6M$514.5M$424.8M$258.1M$240.3M$277.0M$153.7M$153.8M
Free cash flow$3.97B$3.68B$5.42B$6.56B$3.81B$3.38B$1.14B$1.27B$2.72B$2.05B

Balance sheet and shares

Biogen balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$2.33B$1.57B$1.22B$2.91B$1.33B$2.26B$3.42B$1.05B$2.38B$3.01B
Total debt$6.52B$5.94B$5.94B$4.95B$7.91B$6.69B$6.71B$7.28B$4.97B$6.66B
Shareholders' equity$12.14B$12.61B$13.04B$13.34B$10.70B$10.90B$13.40B$14.80B$16.72B$18.26B
Diluted shares219M213M205M187M161M150M146M146M146M147M

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Biogen quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$2.45B$2.43B$2.65B$2.53B$2.28B$2.48B$2.74B$2.80B
Revenue, year on year+2.9%+6.1%+7.3%+2.8%−7.1%+1.9%+3.4%+10.6%
Gross margin76.2%74.1%77.1%73.4%78.3%73.3%71.6%73.3%
Operating income$635.1M$311.2M$744.0M$557.3M$249.6M$377.7M$132.4M−$9.00M
Net income$266.7M$240.5M$634.8M$466.5M−$48.90M$319.5M$97.50M−$20.60M
Diluted EPS$1.83$1.64$4.33$3.17−$0.33$2.15$0.66−$0.14
Free cash flow$721.6M$222.2M$134.3M$1.23B$468.0M$594.3M$408.0M$600.4M

Operating KPIs

The operating figures Biogen reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Biogen operating KPIs
KPILatestPeriodChange on a yearRecent periods
Product revenue, net revenue$2.1Bquarter to 30 Sep 2026up 13.1%
MS Product Revenues$919.3Mquarter to 30 Sep 2026down 13.4%
Rare Disease Product Revenue$676.3Mquarter to 30 Sep 2026up 26.8%
Revenue from anti-CD20 therapeutic programs revenue$497.3Mquarter to 30 Sep 2026up 0.7%
SPINRAZA revenue$460.6Mquarter to 30 Sep 2026up 23.2%
TYSABRI revenue$437.1Mquarter to 30 Sep 2026up 1.2%
Royalty Attributed To OCREVUS revenue$369.9Mquarter to 30 Sep 2026down 4.3%
Fumarate revenue$274.0Mquarter to 30 Sep 2026down 28.4%
Specialized Immunology revenue$242.8Mquarter to 30 Sep 2026—
Interferon revenue$208.2Mquarter to 30 Sep 2026down 15.7%
VUMERITY revenue$192.0Mquarter to 30 Sep 2026down 10.5%
SYFOVRE revenue$191.3Mquarter to 30 Sep 2026—
SKYCLARYS revenue$178.2Mquarter to 30 Sep 2026up 34.1%
Biosimilars revenue$165.9Mquarter to 30 Sep 2026down 15.7%
AVONEX revenue$156.6Mquarter to 30 Sep 2026down 16.9%
Contract manufacturing, royalty and other revenue$149.7Mquarter to 30 Sep 2026down 1.0%
Contract manufacturing revenue$135.9Mquarter to 30 Sep 2026down 4.0%
BENEPALI revenue$117.3Mquarter to 30 Sep 2026down 3.8%
ZURZUVAE revenue$84.4Mquarter to 30 Sep 2026up 52.6%
TECFIDERA revenue$82.0Mquarter to 30 Sep 2026down 51.2%
Alzheimer's Collaboration revenue$68.4Mquarter to 30 Sep 2026up 60.2%
PLEGRIDY revenue$51.6Mquarter to 30 Sep 2026down 11.6%
EMPAVELI revenue$51.5Mquarter to 30 Sep 2026—
IMRALDI revenue$42.0Mquarter to 30 Sep 2026down 20.2%
QALSODY revenue$37.5Mquarter to 30 Sep 2026up 42.0%
Royalty and other revenue$13.8Mquarter to 30 Sep 2026up 42.3%
FLIXABI revenue$6.4Mquarter to 30 Sep 2026down 58.2%
BYOOVIZ revenue$200,000quarter to 30 Sep 2026down 97.1%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Biogen's revenue in fiscal 2025?

$9.89 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Biogen's net income in fiscal 2025?

$1.29 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Biogen's diluted earnings per share in fiscal 2025?

$8.79 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Biogen's gross margin?

75.7% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Biogen's operating margin?

18.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Biogen generate in fiscal 2025?

$2.05 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Biogen's revenue come from?

In fiscal 2025, by product: Revenue from anti-CD20 therapeutic programs $1.86B (19%), SPINRAZA $1.55B (16%), Fumarate $1.43B (14%), Interferon $945.6M (9.6%), out of $9.89B in all, as stated in its annual report.

In the terminal

Twenty years of Biogen's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans